SPRY · ARS Pharmaceuticals, Inc.
$5.93
-0.07 (-1.17%)
At close · Jul 24
Market Cap
$589.86M
Shares
99.30M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$6.00
Open$6.10
Day$5.77–6.10
52W$5.77–18.63
Avg vol 30d2.1M
Short int22.7M · 22.8% float · 15.3d
Short vol63%
Last earningsMay 15, 2026
DataDec 2020–Jul 2026
Filing10-Q · May 15
Up next
Next earnings call
Aug 13, 2026
Est · unconfirmed
· in 3 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 15, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 18.6 · elevated
Equity put/call 0.79
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−34%
below
Price vs 50-day avg
−29%
below
RSI (14)
25
oversold
MACD trend
Negative
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−43%
trailing
6-month return
−41%
trailing
YTD return
−49%
this year
Relative strength
−48%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $8 › 200d $9 — 200d above 50d
Institutional flow
Accumulating
26 of 203 funds reported for Jun 30 · net +856.0K sh shares · +7 new
Insider flow
Distributing
Net -$283.6K over 90 days · 100% sells
Short interest
Rising
22.83% of float · ▲ +4.3% MoM · 15.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
203 holders — near 3-yr high, broad support
Squeeze score
79
high risk · 0–100
Fundamentals
Revenue growth
−5%
Y/Y
EPS growth
−2275%
Y/Y
Free cash flow
$-171.2M
Balance sheet
$55.1M
net debt
Quant / Vol
risk profile
Volatility
71%
annualized · 1-yr
Max drawdown
−67%
past year
ATR
9.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−34%
Bearish
Price vs 50-day avg
−29%
Bearish
RSI (14)
25
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $8 › 200d $9 — 200d above 50d
Institutional flow
Accumulating
26 of 203 funds reported for Jun 30 · net +856.0K sh shares · +7 new
Insider flow
Distributing
Net -$283.6K over 90 days · 100% sells
Short interest
Rising
22.83% of float · ▲ +4.3% MoM · 15.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
203 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $6
Now $6 · 2%
52-wk high $19
vs 200-day avg -34%
vs 50-day avg -29%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Sales force representatives | 148 | Q1 2026 | — |
| Healthcare providers who have prescribed neffy | 22,500 | to date | — |
| Repeat prescribers | 50% | to date | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
SPRY
this stock
ARS Pharmaceuticals, Inc.
|
$589.86M | -48.5% | -5.5% | — | 22.8% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.6% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.16B | +4.4% | +46.2% | 28.3 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.78B | -15.4% | +20.8% | 16.0 | 3.3% |
|
ARGX
Argenx SE
|
$57.44B | +9.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| SPRY | -19.6% | -43.1% | -41.3% | -25.1% | -48.5% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | -17.9% | -43.7% | -47.7% | -23.9% | -56.8% |